Abstract: A process for producing an aqueous coating composition comprises providing an aqueous polymer dispersion having a pH <7 and adding to the dispersion 1 to 30 ppm of 5-chloro-2-methyl-3(2H)-isothiazolone (CIT) and 10 to 1000 ppm of 2,2-dibro-mo-3-nitrilopropionamide (DBNPA), all by weight of the total weight of the dispersion. At least one adjuvant is also added to the dispersion to produce a coating composition. When the coating composition is to be put into service, the DBNPA is decomposed by raising the pH of the coating composition and the CIT is decomposed either by raising the pH of the coating composition or by adding a CIT-decomposing compound to the coating composition.

Abstract: An aqueous polymer dispersion is produced by multistage emulsion polymerization, in which a monomer composition I comprising 19 to 29 wt % hard monomers and 64 to 74 wt % soft monomers is polymerized to produce a first polymer phase and then a monomer composition II comprising 65 to 95 wt % hard monomers and 5 to 35 wt % soft monomers is polymerized to produce a second polymer phase. Monomer composition I also comprises from 1 to 5 wt % of at least one monomer selected from ethylenically unsaturated sulfonic acids, phosphonic acids, phosphoric acids, carboxylic acids, carboxylic amides, carboxylic anhydrides and mixtures thereof and 1 to 7.5 wt % of ethylenically unsaturated monomers containing keto groups. The weight ratio of monomer composition I to monomer composition II ranges from 50:50 to 65:35 and the polymer dispersion also contains a water-soluble cross-linking component selected from polyfunctional carboxylic hydrazides and/or polyfunctional amines.

Abstract: An aqueous polymer dispersion is produced by multistage emulsion polymerization, in which a monomer composition I comprising 19 to 29 wt % hard monomers and 64 to 74 wt % soft monomers is polymerized to produce a first polymer phase and then a monomer composition II comprising 65 to 95 wt % hard monomers and 5 to 35 wt % soft monomers is polymerized to produce a second polymer phase. Monomer composition I also comprises from 1 to 5 wt % of at least one monomer selected from ethylenically unsaturated sulfonic acids, phosphonic acids, phosphoric acids, carboxylic acids, carboxylic amides, carboxylic anhydrides and mixtures thereof and 1 to 7.5 wt % of ethylenically unsaturated monomers containing keto groups. The weight ratio of monomer composition I to monomer composition II ranges from 50:50 to 65:35 and the polymer dispersion also contains a water-soluble cross-linking component selected from polyfunctional carboxylic hydrazides and/or polyfunctional amines.

Abstract: The present invention relates to a process for the emulsion polymerization of free-radically polymerizable, ethylenically unsaturated main monomers, and optionally further auxiliary monomers copolymerizable therewith, wherein the polymerization comprises a polymerization reaction phase starting with the first addition of an initiator or starting with the first addition of monomers, whatever is later, and ending with the completion of the addition of the initiator or the completion of the addition of total monomers, whatever is later, wherein the reaction temperature is increased during said polymerization reaction phase from a start temperature in the range of about 30° C. to about 85° C. to an end temperature in the range of about 60° C. to about 160° C., and wherein the polymerization temperature is increased for at least 25% of the duration of said polymerization reaction phase.

Abstract: What are described are coating compositions comprising pigments and/or fillers and multistage polyvinyl ester dispersions as binders. These binders are produced by a selected multistage process in which a polyvinyl ester dispersion is obtained in a first stage, monomers in dissolved or pure form or in the form of an emulsion are added to the reaction mixture in a second stage and then the polymerization is started again. The polyvinyl ester dispersions comprise polymerized silanes and/or epoxides or the polyvinyl ester dispersions have only a small content of protective colloids, if any. The coating compositions formulated with the multistage polyvinyl ester dispersions obtained in this way are notable for a very high weathering resistance.

Abstract: Aqueous copolymer dispersions for a variety of uses, including coating compositions or binders for plasters and paints, are disclosed. The aqueous copolymer dispersions may comprise one or more silicon containing compounds, in particular hydrolyzable silane compounds without any additional reactive group.

Abstract: The present invention relates to nucleotide sequences coding for human porphobilinogen deaminase that are optimised for higher expression in mammalian cells. The invention further relates to DNA constructs comprising such optimised synthetic coding sequences for use in gene therapy of conditions caused by a deficiency in porphobilinogen deaminase, such as acute intermittent porphyria. Accordingly, the present invention relates to a nucleic acid or a nucleic acid construct comprising a nucleotide sequence coding for a human porphobilinogen deaminase, wherein at least 320 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 1 or wherein at least 305 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 3.

Abstract: Aqueous copolymer dispersions for a variety of uses, including coating compositions or binders for plasters and paints, are disclosed. The aqueous copolymer dispersions may comprise one or more silicon containing compounds, in particular hydrolyzable silane compounds without any additional reactive group.

Abstract: The invention provides a method for the treatment of cirrhosis and liver fibrosis by the use or viral vectors containing the gene encoding IGF-I. The invention discloses both parvoviral vectors and SV40-based vectors as well uses thereof for the treatment of cirrhosis and gene therapy and methods for the preparation of said viral vectors.

Abstract: The invention provides a method for the treatment of cirrhosis and liver fibrosis by the use or viral vectors containing the gene encoding IGF-I. The invention discloses both parvoviral vectors and SV40-based vectors as well uses thereof for the treatment of cirrhosis and gene therapy and methods for the preparation of said viral vectors.

Abstract: The present invention relates to an alanine glyoxylate aminotransferase (AGXT) I340M therapeutic for use as a medicament or in a method of treatment, for example in the treatment of an AGXT-responsive condition. The AGXT I340M therapeutic is an AGXT I340M protein comprising an amino acid sequence, which, when optimally aligned with SEQ ID NO: 2, comprises a methionine at a position corresponding to position 340 in SEQ ID NO: 2, a nucleic acid molecule encoding such an AGXT I340M protein, or a virion of a viral gene therapy vector comprising such a nucleic acid molecule. The AGXT I340M therapeutic has a higher specific activity as compared to other AGXT alleles and may therefore be advantageously used in the treatment of primary hyperoxaluria type I.

Abstract: A description is given of a process of emulsion polymerization of free-radically polymerizable ethylenically unsaturated monomers selected from the group of the monoesters or diesters of ethylenically unsaturated monocarboxylic or dicarboxylic acids with alkanols, vinyl esters and/or vinylaromatics and, if desired, further monomers copolymerizable therewith, at least 60% of the total conversion in the polymerization taking place at a temperature of 100° C. to 160° C., the polymerization being performed in the presence of emulsifiers and an amount of 0% to 1% by weight, based on the total amount of the monomers used, of protective colloid. The process can be used to obtain significantly faster conversions for comparable quality of the process products. The dispersions obtained can be employed in a wide variety of different applications, such as binders for paints or as adhesives.

Abstract: The present invention relates to nucleotide sequences coding for human porphobilinogen deaminase that are optimised for higher expression in mammalian cells. The invention further relates to DNA constructs comprising such optimised synthetic coding sequences for use in gene therapy of conditions caused by a deficiency in porphobilinogen deaminase, such as acute intermittent porphyria. Accordingly, the present invention relates to a nucleic acid or a nucleic acid construct comprising a nucleotide sequence coding for a human porphobilinogen deaminase, wherein at least 320 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 1 or wherein at least 305 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 3.

Abstract: Multistage polymers predominantly stabilized by nonionic emulsifiers and derived from hard and soft monomer compositions containing vinyl esters, of which at least one monomer composition must contain an unsaturated compromisable organosilicon compound, are described. The plastic dispersions can be used as binders in emulsion paints and finishes and impart to these excellent scrub resistance in addition to good blocking resistance.

Abstract: Multistage polymers predominantly stabilized by nonionic emulsifiers and derived from hard and soft monomer compositions containing vinyl esters, of which at least one monomer composition must contain an unsaturated compromisable organosilicon compound, are described. The plastic dispersions can be used as binders in emulsion paints and finishes and impart to these excellent scrub resistance in addition to good blocking resistance.

Abstract: A description is given of a process of emulsion polymerization of free-radically polymerizable ethylenically unsaturated monomers selected from the group of the monoesters or diesters of ethylenically unsaturated monocarboxylic or dicarboxylic acids with alkanols, vinyl esters and/or vinylaromatics and, if desired, further monomers copolymerizable therewith, at least 60% of the total conversion in the polymerization taking place at a temperature of 100° C. to 160° C., the polymerization being performed in the presence of emulsifiers and an amount of 0% to 1% by weight, based on the total amount of the monomers used, of protective colloid. The process can be used to obtain significantly faster conversions for comparable quality of the process products. The dispersions obtained can be employed in a wide variety of different applications, such as binders for paints or as adhesives.

Abstract: What are described are coating compositions comprising pigments and/or fillers and multistage polyvinyl ester dispersions as binders. These binders are produced by a selected multistage process in which a polyvinyl ester dispersion is obtained in a first stage, monomers in dissolved or pure form or in the form of an emulsion are added to the reaction mixture in a second stage and then the polymerization is started again. The polyvinyl ester dispersions comprise polymerized silanes and/or epoxides or the polyvinyl ester dispersions have only a small content of protective colloids, if any. The coating compositions formulated with the multistage polyvinyl ester dispersions obtained in this way are notable for a very high weathering resistance.

Abstract: A description is given of coating compositions comprising at least one pigment and/or filler and at least one aqueous dispersion of a selected emulsifier-stabilized vinyl ester copolymer which comprises as its stabilizer a mixture of at least one nonionic emulsifier and at least one salt of a bisester of a sulfonated dicarboxylic acid having 4 to 8 carbon atoms. The coating compositions formulated with these binders feature high scrub resistance.

Abstract: The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and uses thereof for treatment of disease.

Abstract: The present invention relates to aqueous plastic material dispersions based on vinyl ester copolymers, having a solids content of up to 80% by weight and a minimum film formation temperature below 20° C., which is substantially stabilized by ionic components, the vinyl ester copolymers containing at least one homo- or copolymer A and at least one homo- or copolymer B, methods for producing the same and the use thereof.